Related Experiment Video

Updated: Feb 25, 2026

Merkel Cell Polyomavirus Infection and Detection
13:45

Merkel Cell Polyomavirus Infection and Detection

Published on: February 7, 2019

10.4K

Tropomyosin Receptor Kinase A Expression on Merkel Cell Carcinoma Cells

Ulrike Wehkamp1, Sophie Stern1, Sandra Krüger2

  • 1Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.

JAMA Dermatology
|August 10, 2017
PubMed
Abstract

Insights

Tropomyosin receptor kinase A (TrkA) is expressed in all Merkel cell carcinoma (MCC) tumor cells. This finding supports TrkA as a potential therapeutic target for MCC, particularly for patients unresponsive to current immunotherapies.

Area of Science:

  • Oncology
  • Dermatology
  • Molecular Biology

Background:

  • Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer.
  • While immune checkpoint inhibitors have shown efficacy, a significant portion of patients do not respond.
  • Tropomyosin receptor kinase A (TrkA) targeted therapy is emerging as a promising approach in various cancers.

Purpose of the Study:

  • To investigate the expression of TrkA in Merkel cell carcinoma (MCC) specimens.
  • To evaluate the potential of TrkA as a therapeutic target for MCC.

Main Methods:

  • A case series study involving 55 MCC patients.
  • Immunohistochemical analysis was performed on 39 suitable tumor specimens.
  • TrkA expression was assessed on tumor cells, alongside diagnostic markers CK20 and synaptophysin.

Main Results:

  • All 36 evaluable MCC specimens (100%) showed TrkA expression on tumor cells.
  • Weak cytoplasmic expression was observed in 94% of cases, with strong expression in 6%.
  • Positive perinuclear dots were noted in 83% of specimens.

Conclusions:

  • Tropomyosin receptor kinase A (TrkA) is ubiquitously expressed in Merkel cell carcinoma (MCC) tumor cells.
  • This high expression rate suggests TrkA as a potential therapeutic target for MCC.
  • TrkA-targeted therapy could offer new treatment avenues for patients resistant to immune checkpoint inhibitors.

More Related Videos

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.7K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.9K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.8K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
19.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K